BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel ...

BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its ...

On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

The recession in the automotive industry is in its early phases. This is already hurting the prospects of parts suppliers, such as Magna International (MGA), Advance Auto Parts (AAP), and Aptiv (APTV) ...

The BioNTech SE ADR BNTX slid 2.22% to $106.32 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 and Dow Jones ...

From continental Europe, the gainers were led by biotech company BioNTech (BNTX) and 3D printer company Materialise (MTLS), which rose 4.4% and 4.1% respectively. They were followed by ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

BNT327 has been tested in clinical trials with tumour patients, and Biotheus previously held the rights to commercialize it ...

Harding Loevner International Equity ADR composite rose 9.2%, gross, in Q3 2024, outpacing the 8.2% gain of the MSCI All ...